title: Letter: Limitations of studies to evaluate the significance of anti-tumour necrosis factor serum levels in Crohn's disease--authors' reply.
authors.affiliation: Robarts Clinical Trials, Inc., Robarts Research Institute, Western University, London, ON, Canada; Division of Gastroenterology, University of California San Diego, La Jolla, CA, USA.
authors.forename: B G
authors.initials: BG
authors.lastname: Levesque
authors.forename: B G
authors.initials: BG
authors.lastname: Feagan
mesh_terms: D000911:Antibodies, Monoclonal / Q000097:blood*; D002097:C-Reactive Protein / Q000378:metabolism*; D003424:Crohn Disease / Q000188:drug therapy*; D005260:Female; D005765:Gastrointestinal Agents / Q000097:blood*; D006801:Humans; D000069285:Infliximab; D008297:Male
chemical_list: D000911:Antibodies, Monoclonal; D005765:Gastrointestinal Agents; D002097:C-Reactive Protein; D000069285:Infliximab